Table 6.

Adverse Events

	Placebo (n = 63)	Ato75 (n = 63)	AD109 2.5/75 mg (n = 42)	AD109 5/75 mg (n = 41)
Any adverse event	25 (39.7%)	51 (81%)	26 (61.9%)	32 (78%)
Adverse event leading to discontinuation	1 (2%)	12 (19%)	5 (12%)	5 (12%)
Most common adverse events*
Dry mouth	3 (5%)	17 (27%)	10 (24%)	24 (59%)
Insomnia	2 (3%)	23 (37%)	11 (26%)	9 (22%)
Urinary hesitation/flow decrease	0	14 (22%)	3 (7%)	9 (22%)
Constipation	2 (3%)	2 (3%)	0	5 (12%)
Nausea	2 (3%)	4 (6%)	5 (12%)	4 (10%)
Decreased appetite	1 (2%)	5 (8%)	2 (5%)	4 (10%)
Feeling jittery	1 (2%)	2 (3%)	2 (5%)	3 (7%)
Somnolence	1 (2%)	0	1 (2%)	3 (7%)

Definition of abbreviation: Ato75 = atomoxetine 75 mg.

^*Most common adverse events are those reported in at least three participants in any treatment group.